Is it reasonable to administer pegfilgrastim on day 1 of a myelosuppressive chemotherapy regimen? A cost-utility analysis.

Billingsley, Caroline C

Is it reasonable to administer pegfilgrastim on day 1 of a myelosuppressive chemotherapy regimen? A cost-utility analysis. [electronic resource] - Cancer treatment and research communications 2018 - 21-25 p. digital

Publication Type: Journal Article

2468-2942

10.1016/j.ctarc.2017.11.003 doi


Antineoplastic Agents--therapeutic use
Cost-Benefit Analysis
Drug Administration Schedule
Febrile Neutropenia--chemically induced
Female
Filgrastim--administration & dosage
Humans
Ovarian Neoplasms--drug therapy
Polyethylene Glycols--administration & dosage
Primary Prevention
Quality of Life
Quality-Adjusted Life Years
Risk Factors